Since Greg Cox was a boy, sports had been an integral part of his life. From lacrosse to running marathons to waterskiing, he did it all. When he reached adulthood and ankle arthritis made the simple act of walking painful, he knew he needed to take action. After a second opinion and ankle replacement surgery at Duke, Cox, age 57, is back to the active life he loves.
After two rounds of cancer treatment, Sasha Zarzour didn’t think she’d be able to get pregnant. But with specialized care at the Duke Fertility Center and constant support from infertility specialists, Sasha and her husband, Billy, found hope.
“We wanted a family for so long and to know it may not happen was a struggle,” she said. “But to have a team who have helped so many people have a baby and who know how to support you, it helps you push through.”
Men with advanced metastatic prostate cancer that has not responded to other treatments may now benefit from a new radiopharmaceutical treatment called PLUVICTOTM (lutetium Lu 177 vipivotide tetraxetan). Duke is one of the first cancer centers in the Southeastern region to offer PLUVICTOTM following its FDA approval in March 2022. Studies show it can extend the lives of people with this aggressive form of prostate cancer, even in the late stages, said Terence Wong MD, PhD, a nuclear radiologist at Duke Health.